Metabolic Response to Beverages With Various Sweetening Systems Consumed During Meal in Overweight and Obese Subjects

NCT ID: NCT02932423

Last Updated: 2017-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-18

Study Completion Date

2017-07-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical study is to investigate the effect of drinking a sugar-sweetened beverage along with a meal on insulin concentrations and, glucose and lipid metabolism, in overweight and obese subjects, during a 10-hour visit.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight and Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 - Snack

Each subject will consume 6 beverages with varying sugar content at lunch (500 ml) and with a snack in the afternoon (330 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.

Group Type OTHER

Control product E

Intervention Type OTHER

Plain water

Test product A

Intervention Type OTHER

Beverage with no sugar but sweetener

Test product B

Intervention Type OTHER

Beverage with 22 g/L sugar and sweetener

Test product C

Intervention Type OTHER

Beverage with 33 g/L sugar and sweetener

Test product D

Intervention Type OTHER

Beverage with 47 g/L sugar and sweetener

Comparative product F

Intervention Type OTHER

Beverage with 98 g/L sugar

2 - No snack

Each subject will consume 6 beverages with varying sugar content only at lunch (500 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.

Group Type OTHER

Control product E

Intervention Type OTHER

Plain water

Test product A

Intervention Type OTHER

Beverage with no sugar but sweetener

Test product B

Intervention Type OTHER

Beverage with 22 g/L sugar and sweetener

Test product C

Intervention Type OTHER

Beverage with 33 g/L sugar and sweetener

Test product D

Intervention Type OTHER

Beverage with 47 g/L sugar and sweetener

Comparative product F

Intervention Type OTHER

Beverage with 98 g/L sugar

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Control product E

Plain water

Intervention Type OTHER

Test product A

Beverage with no sugar but sweetener

Intervention Type OTHER

Test product B

Beverage with 22 g/L sugar and sweetener

Intervention Type OTHER

Test product C

Beverage with 33 g/L sugar and sweetener

Intervention Type OTHER

Test product D

Beverage with 47 g/L sugar and sweetener

Intervention Type OTHER

Comparative product F

Beverage with 98 g/L sugar

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject, upon briefing of the content of the present study, fully understanding and agreeing to its objective and having given written (dated and signed) informed consent form to take part in the study
* Subject who is able to communicate well with the investigator and to comply with the requirements of the entire study
* If of child bearing potential, female subject must be using or complying with one of the following medically approved methods of contraception such as, but not exclusively: oral birth control pills (at least 1 full monthly cycle prior to study product administration); intra-uterine device (IUD); double barrier methods (such as condoms and spermicide)
* Subject with a body mass index (BMI) between 25 and 35 kg/m² inclusive

Exclusion Criteria

* Pregnant woman, based on positive urine pregnancy test, or planning to become pregnant during the study or breast-feeding woman
* Surgical operation on digestive tract, except appendectomy
* Subject who had any surgery or intervention requiring a general anaesthesia in the preceding 4 weeks, or who plans to have one during the course of the study
* Subject with diagnosed or suspected allergy or hypersensitivity to any food ingredient, including components of the study products (ingredients of sugar-sweetened beverages)
* Blood donation within the last 3 months or planning to give blood during the course of the study
* Subject involved in any other clinical study within the preceding month or in the exclusion period after another clinical study
* Subject in a situation, which in the Investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject
* Evidence of clinically relevant cardiovascular, metabolic, hematologic, hepatic, gastrointestinal, renal, pulmonary, endocrine or psychiatric history of disease as determined by medical history, physical examination, and vital signs
* Clinically significant abnormal results for urine or blood analyses
Minimum Eligible Age

25 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Danone Global Research & Innovation Center

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeanne BOTTIN, PhD

Role: STUDY_CHAIR

Danone Research, Palaiseau, France

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Eurofins Optimed

Gières, Auvergne-Rhône-Alpes, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NU377

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.